2021 Q1 Form 10-Q Financial Statement
#000156459021025060 Filed on May 06, 2021
Income Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| Revenue | $0.00 | $4.081M |
| YoY Change | -100.0% | 5.05% |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $8.430M | $8.730M |
| YoY Change | -3.44% | -8.3% |
| % of Gross Profit | ||
| Research & Development | $18.55M | $23.05M |
| YoY Change | -19.51% | 1.52% |
| % of Gross Profit | ||
| Depreciation & Amortization | $107.0K | $115.0K |
| YoY Change | -6.96% | -14.81% |
| % of Gross Profit | ||
| Operating Expenses | $27.26M | $31.78M |
| YoY Change | -14.22% | -1.38% |
| Operating Profit | -$27.26M | -$27.69M |
| YoY Change | -1.57% | -2.27% |
| Interest Expense | $60.00K | $1.040M |
| YoY Change | -94.23% | -18.75% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $58.00K | $1.039M |
| YoY Change | -94.42% | -18.64% |
| Pretax Income | -$27.20M | -$26.66M |
| YoY Change | 2.04% | -1.49% |
| Income Tax | $0.00 | |
| % Of Pretax Income | ||
| Net Earnings | -$27.20M | -$26.66M |
| YoY Change | 2.04% | -1.47% |
| Net Earnings / Revenue | -653.15% | |
| Basic Earnings Per Share | -$0.76 | |
| Diluted Earnings Per Share | -$685.5K | -$0.76 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 32.62M | |
| Diluted Shares Outstanding | 35.08B |
Balance Sheet
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $214.9M | $249.1M |
| YoY Change | -13.74% | 28.75% |
| Cash & Equivalents | $78.25M | $42.33M |
| Short-Term Investments | $136.6M | $206.8M |
| Other Short-Term Assets | $6.500M | $4.600M |
| YoY Change | 41.3% | 6.98% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $200.0K | $3.100M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $221.6M | $256.8M |
| YoY Change | -13.69% | 27.86% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $9.600M | $1.780M |
| YoY Change | 439.33% | -14.38% |
| Goodwill | $12.64M | |
| YoY Change | 0.0% | |
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $6.000M | $1.661M |
| YoY Change | 261.23% | 0.0% |
| Total Long-Term Assets | $57.30M | $56.56M |
| YoY Change | 1.31% | -3.22% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $221.6M | $256.8M |
| Total Long-Term Assets | $57.30M | $56.56M |
| Total Assets | $278.9M | $313.3M |
| YoY Change | -10.98% | 20.85% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $3.600M | $2.104M |
| YoY Change | 71.1% | -12.33% |
| Accrued Expenses | $3.659M | $4.430M |
| YoY Change | -17.4% | -56.32% |
| Deferred Revenue | $6.715M | |
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $14.50M | $21.15M |
| YoY Change | -31.43% | -16.1% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $14.60M | $37.90M |
| YoY Change | -61.48% | -6.19% |
| Total Long-Term Liabilities | $14.60M | $37.90M |
| YoY Change | -61.48% | -6.19% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $14.50M | $21.15M |
| Total Long-Term Liabilities | $14.60M | $37.90M |
| Total Liabilities | $31.70M | $61.54M |
| YoY Change | -48.49% | -10.61% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$466.1M | |
| YoY Change | 26.36% | |
| Common Stock | $717.9M | |
| YoY Change | 2761169.23% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $247.2M | $251.8M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $278.9M | $313.3M |
| YoY Change | -10.98% | 20.85% |
Cashflow Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$27.20M | -$26.66M |
| YoY Change | 2.04% | -1.47% |
| Depreciation, Depletion And Amortization | $107.0K | $115.0K |
| YoY Change | -6.96% | -14.81% |
| Cash From Operating Activities | -$33.34M | -$25.22M |
| YoY Change | 32.22% | 5.34% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $3.078M | $65.00K |
| YoY Change | 4635.38% | -95.63% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $21.09M | $20.76M |
| YoY Change | 1.59% | 60.68% |
| Cash From Investing Activities | $18.02M | $20.69M |
| YoY Change | -12.94% | 80.96% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $34.14M | $0.00 |
| YoY Change | -100.0% | |
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 34.14M | 119.0K |
| YoY Change | 28586.55% | -15.0% |
| NET CHANGE | ||
| Cash From Operating Activities | -33.34M | -25.22M |
| Cash From Investing Activities | 18.02M | 20.69M |
| Cash From Financing Activities | 34.14M | 119.0K |
| Net Change In Cash | 18.81M | -4.406M |
| YoY Change | -526.9% | -64.36% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$33.34M | -$25.22M |
| Capital Expenditures | $3.078M | $65.00K |
| Free Cash Flow | -$36.42M | -$25.28M |
| YoY Change | 44.06% | -0.57% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
18554000 | |
| CY2021Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8704000 | |
| CY2020Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8729000 | |
| CY2021Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
27258000 | |
| CY2020Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
31775000 | |
| CY2021Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-27258000 | |
| CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-27694000 | |
| CY2021Q1 | us-gaap |
Interest Income Other
InterestIncomeOther
|
58000 | |
| CY2020Q1 | us-gaap |
Interest Income Other
InterestIncomeOther
|
1039000 | |
| CY2021Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
58000 | |
| CY2020Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1039000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-27200000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-26655000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-1000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
115000 | |
| CY2021Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-27201000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-26540000 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.69 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.76 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
39679734 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
35079756 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-27200000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-1027000 | |
| CY2021Q1 | asmb |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-1041000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-26655000 | |
| CY2021Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
107000 | |
| CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
115000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
-286000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4924000 | |
| CY2021Q1 | asmb |
Accretion And Amortization Of Investments In Marketable Debt Securities
AccretionAndAmortizationOfInvestmentsInMarketableDebtSecurities
|
-92000 | |
| CY2020Q1 | asmb |
Accretion And Amortization Of Investments In Marketable Debt Securities
AccretionAndAmortizationOfInvestmentsInMarketableDebtSecurities
|
135000 | |
| CY2021Q1 | asmb |
Noncash Rent Expense
NoncashRentExpense
|
1135000 | |
| CY2020Q1 | asmb |
Noncash Rent Expense
NoncashRentExpense
|
1151000 | |
| CY2021Q1 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
-1611000 | |
| CY2020Q1 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
0 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-319000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-303000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-795000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-358000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-23000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1036000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
373000 | |
| CY2021Q1 | asmb |
Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
|
-102000 | |
| CY2020Q1 | asmb |
Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
|
-193000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-8312000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-3808000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
0 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-1007000 | |
| CY2020Q1 | asmb |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-1120000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-33344000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-25218000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
3078000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
65000 | |
| CY2021Q1 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
857000 | |
| CY2020Q1 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
0 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
49213000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
44242000 | |
| CY2021Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
66450000 | |
| CY2020Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
55000000 | |
| CY2021Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
3000000 | |
| CY2020Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
10000000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
18016000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
20693000 | |
| CY2021Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | |
| CY2020Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
119000 | |
| CY2021Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
34137000 | |
| CY2020Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
34137000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
119000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
18809000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-4406000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
59444000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
46732000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
78253000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
42326000 | |
| CY2021Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
42000 | |
| CY2020Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
362000 | |
| CY2021Q1 | asmb |
Remeasurement Of Lease Liabilities Arising From Modification Of Right Of Use Assets
RemeasurementOfLeaseLiabilitiesArisingFromModificationOfRightOfUseAssets
|
788000 | |
| CY2020Q1 | asmb |
Remeasurement Of Lease Liabilities Arising From Modification Of Right Of Use Assets
RemeasurementOfLeaseLiabilitiesArisingFromModificationOfRightOfUseAssets
|
0 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
240578000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
34137000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-1000 | |
| CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
-270000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-27200000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
247244000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
273217000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
119000 | |
| CY2021Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2021Q1 | asmb |
Number Of Approved Products
NumberOfApprovedProducts
|
0 | |
| CY2021Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include estimates for the cost-based input of revenue recognition and standalone selling price estimates for allocation of transaction price to performance obligations, revenue recognition, estimates of costs incurred but not yet invoiced for clinical trial accruals, recoverability and useful lives of our long-lived assets, the estimated fair value of our indefinite-lived intangible assets, the estimated fair value of our reporting unit for purposes of evaluating goodwill impairment, provisions for income taxes, amounts receivable under collaboration agreements, measurement of operating lease liabilities, and the fair value of stock options, stock appreciation rights, and restricted stock units (RSUs) granted to employees, directors, and consultants.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible these external factors could have an effect on the Company’s estimates and could cause actual results to differ materially from those estimates and assumptions.</p> | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.69 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.76 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-27200000 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
39679734 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
35079756 | |
| CY2021Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8093959 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7418558 | |
| CY2021Q1 | asmb |
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
|
203131000 | |
| CY2021Q1 | asmb |
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
|
2000 | |
| CY2021Q1 | asmb |
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
|
8000 | |
| CY2021Q1 | asmb |
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
|
203125000 | |
| CY2020Q4 | asmb |
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
|
211017000 | |
| CY2020Q4 | asmb |
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
|
7000 | |
| CY2020Q4 | asmb |
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
|
4000 | |
| CY2020Q4 | asmb |
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
|
211020000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
0 | |
| CY2021Q1 | asmb |
Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
|
0 | |
| CY2020Q4 | asmb |
Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
|
0 | |
| CY2021Q1 | asmb |
Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
|
1246000 | |
| CY2020Q4 | asmb |
Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
|
4164000 | |
| CY2021Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1842000 | |
| CY2020Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
7016000 | |
| CY2021Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
571000 | |
| CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
807000 | |
| CY2021Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
3659000 | |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
11987000 | |
| CY2021Q1 | us-gaap |
Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
|
6988000 | |
| CY2021Q1 | asmb |
Restructuring And Related Cost Incurred Cost Benefit
RestructuringAndRelatedCostIncurredCostBenefit
|
-1052000 | |
| CY2021Q1 | us-gaap |
Restructuring And Related Cost Cost Incurred To Date1
RestructuringAndRelatedCostCostIncurredToDate1
|
6726000 | |
| CY2021Q1 | asmb |
Restructuring And Related Cost Incurred Cost Benefit
RestructuringAndRelatedCostIncurredCostBenefit
|
-1052000 | |
| CY2020Q1 | asmb |
Restructuring And Related Cost Incurred Cost Benefit
RestructuringAndRelatedCostIncurredCostBenefit
|
0 | |
| CY2020Q4 | asmb |
Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
|
4164000 | |
| CY2021Q1 | us-gaap |
Restructuring Charges
RestructuringCharges
|
1611000 | |
| CY2021Q1 | us-gaap |
Payments For Restructuring
PaymentsForRestructuring
|
4529000 | |
| CY2021Q1 | asmb |
Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
|
1246000 | |
| CY2021Q1 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
900000 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2020Q3 | asmb |
Initial Public Offering Value Of Shares Authorized
InitialPublicOfferingValueOfSharesAuthorized
|
300000000.0 | |
| CY2020Q3 | asmb |
Initial Public Offering Value Of Shares Authorized
InitialPublicOfferingValueOfSharesAuthorized
|
300000000.0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2021Q1 | asmb |
Number Of Warrants Exercised
NumberOfWarrantsExercised
|
0 | |
| CY2020Q1 | asmb |
Number Of Warrants Exercised
NumberOfWarrantsExercised
|
0 | |
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
1900000 | |
| CY2019Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
3000000 | |
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
4600000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
3.15 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
9.74 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
200000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2021Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
-286000 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4924000 | |
| CY2021Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
|
18600000 | |
| CY2021Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y9M18D | |
| CY2020Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
8987000 | |
| CY2021Q1 | asmb |
Contract With Customer Liability In Additions
ContractWithCustomerLiabilityInAdditions
|
0 | |
| CY2021Q1 | asmb |
Contract With Customer Liability In Deduction
ContractWithCustomerLiabilityInDeduction
|
0 | |
| CY2021Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
8987000 | |
| CY2019Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
37048000 | |
| CY2020Q1 | asmb |
Contract With Customer Liability In Additions
ContractWithCustomerLiabilityInAdditions
|
0 | |
| CY2020Q1 | asmb |
Contract With Customer Liability In Deduction
ContractWithCustomerLiabilityInDeduction
|
1007000 | |
| CY2020Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
36041000 | |
| CY2021Q1 | us-gaap |
Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
|
800000 | |
| CY2021Q1 | asmb |
Performance Milestone Payment
PerformanceMilestonePayment
|
0 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
8600000 | |
| CY2021Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
8100000 | |
| CY2021Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1135000 | |
| CY2020Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1151000 | |
| CY2021Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
103000 | |
| CY2020Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
100000 | |
| CY2021Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
343000 | |
| CY2020Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
284000 | |
| CY2021Q1 | us-gaap |
Sublease Income
SubleaseIncome
|
27000 | |
| CY2021Q1 | us-gaap |
Lease Cost
LeaseCost
|
1554000 | |
| CY2020Q1 | us-gaap |
Lease Cost
LeaseCost
|
1535000 | |
| CY2021Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1041000 | |
| CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1120000 | |
| CY2021Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
42000 | |
| CY2020Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
362000 | |
| CY2021Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y8M12D | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y8M12D | |
| CY2021Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.097 | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.092 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
2724000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
3612000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
3460000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
9796000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
1218000 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
8578000 |
